Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Edwards Lifesciences ( (EW) ) just unveiled an announcement.
On October 30, 2025, Edwards Lifesciences announced that its Chief Financial Officer, Scott Ullem, will transition from his role by mid-year 2026. The company has started a selection process for a new CFO, ensuring continuity and a smooth transfer of responsibilities, with Ullem continuing in an advisory role post-transition.
The most recent analyst rating on (EW) stock is a Buy with a $98.00 price target. To see the full list of analyst forecasts on Edwards Lifesciences stock, see the EW Stock Forecast page.
Spark’s Take on EW Stock
According to Spark, TipRanks’ AI Analyst, EW is a Outperform.
Edwards Lifesciences’ strong earnings call performance and financial stability are key strengths, driving a positive outlook. However, technical indicators and valuation concerns temper the overall score. Continued focus on cash flow management and addressing competitive pressures will be crucial for sustaining growth.
To see Spark’s full report on EW stock, click here.
More about Edwards Lifesciences
Edwards Lifesciences is a leading global company specializing in structural heart innovations, committed to improving patient lives through breakthrough technologies and partnerships with healthcare stakeholders.
Average Trading Volume: 4,382,040
Technical Sentiment Signal: Buy
Current Market Cap: $48.55B
For detailed information about EW stock, go to TipRanks’ Stock Analysis page.